{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-026779","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2022-10-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.362502+00:00","generated_at":"2026-06-23T01:57:25.962272+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia EVP Research and CMO depart effective Oct 31, 2022","bullets":["Robert Huizinga, EVP Research, and Neil Solomons, CMO, mutually agreed to leave Aurinia.","Huizinga severance: $575,015 base pay, $159,311 vacation, $191,672 bonus target (50% of 2022).","Solomons severance: $698,230 base pay, $192,157 vacation, $232,743 bonus target (50% of 2022).","Both departures effective Oct 31, 2022; benefits coverage for up to 18 months."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-026779","json":"https://secwatch.observer/filing/0001628280-22-026779.json","markdown":"https://secwatch.observer/filing/0001628280-22-026779.md","text":"https://secwatch.observer/filing/0001628280-22-026779.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022026779/0001628280-22-026779-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022026779/auph-20221017.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T01:57:25.962272+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2e268049a8","claim":"Robert Huizinga resigned as Executive Vice President, Research at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022026779/0001628280-22-026779-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Executive Vice President, Research"}],"fact_type":"executive_change"},{"claim_id":"53c4f812b0","claim":"Neil Solomons resigned as Chief Medical Officer at Aurinia Pharmaceuticals Inc..","evidence_excerpt":"On October 17, 2022, Aurinia Pharmaceuticals Inc. and Robert Huizinga, PhD RN, CNeph(C), our Executive Vice President, Research and Neil Solomons, M.D., our Chief Medical Officer, mutually agreed that Dr. Huizinga and Dr. Solomons would cease their employment with Aurinia, each effective October 31, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000162828022026779/0001628280-22-026779-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}